UK markets closed
NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.26 +1.00 (+1.28%) GOLD FUTURES
2,343.30 -31.70 (-1.33%) DOW
39,453.19 -59.65 (-0.15%) Bitcoin GBP
50,236.41 +1,358.12 (+2.78%)
Akebia Therapeutics, Inc. (AX9.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:12AM CEST. Market open.
| Previous close | 1.1500 |
| Open | 1.0920 |
| Bid | 1.1640 x 30000 |
| Ask | 1.1820 x 30000 |
| Day's range | 1.0920 - 1.0920 |
| 52-week range | 0.7410 - 2.8500 |
| Volume | |
| Avg. volume | 534 |
| Market cap | 228.878M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
The analysts covering Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) delivered a dose of negativity to shareholders today...
- GuruFocus.com
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Insights into Akebia Therapeutics' Performance and Strategic Developments
- Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09. AKBA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the Akebia’s […]
© 2024 Yahoo. All rights reserved.